# The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

> **NCT02267525** · PHASE2 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 233 (actual)

## Conditions studied

- Gastroparesis

## Interventions

- **DRUG:** Velusetrag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02267525
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2018-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267525, "The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02267525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*